JPMorgan lifts Edgewise Therapeutics target to $45
Edgewise Therapeutics (NASDAQ:EWTX) received an updated price target from JPMorgan, with analysts at the firm raising their ...
News-Medical.Net13h
A step toward precision medicine: New drug targets for heart failure
A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...
Allogene Therapeutics (ALLO) Gets a Buy from Piper Sandler
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...